# TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

> **NCT03093701** · PHASE2 · COMPLETED · sponsor: **Taiwan Liposome Company** · enrollment: 31 (actual)

## Conditions studied

- Retinal Vein Occlusion
- Macula Edema

## Interventions

- **DRUG:** TLC399 (ProDex)

## Key facts

- **NCT ID:** NCT03093701
- **Lead sponsor:** Taiwan Liposome Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-01
- **Primary completion:** 2019-02-04
- **Final completion:** 2019-02-04
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03093701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03093701, "TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03093701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*